Companies · Biotechnology

Neutrolis Inc.

CAMBRIDGE · Biotechnology

Diligence memoA one-page analyst read on Neutrolis Inc. — recommendation, valuation, rhythm, risks.
$27.6M
Total raised · real
3
Rounds
3.6×
Latest step-up
Top 28%
Sector rank · raised
Series B
Latest stage · inferred · Fri Jun 20 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

Neutrolis Inc. looks under-valued against its niche peers and is active on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.21× the median modeled value of Series B Biotechnology companies in 2025–2027 (94 peers) — value vs value, same stage and era.
Active
  • Last raise 12 mo ago; this sector typically re-raises about every 14 months.
  • Raising on or ahead of the sector's normal rhythm.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Neutrolis Inc. is one of 4293 Biotechnology companies tracked from CAMBRIDGE. By capital raised it ranks in the upper tier (ahead of 73% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
1
Investors (latest)
2025-06-20
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$250M$500M$750M$1.0BSeries B · 2021-09-10 Raised $23M (real) Modeled valuation $550M (est)$23M$550MSeries B2021Series B · 2025-02-28 Raised $965K (real) Modeled valuation $5.2M (est)$965K$5.2MSeries B2025Series B · 2025-06-20 Raised $3.5M (real) Modeled valuation $16M (est)$3.5M$16MSeries B2025+$965K+$3.5MCumulative $28M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series B$23.1M · 2021
Series B extension$965K · 2025
Series B extension$3.5M · 2025

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed, Series A — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 25%.

Modeled valuation trajectory
$16.5M
Base estimate est.
$7.0M
Conservative case
$24.5M
Upside case
$19.4M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ba $15M–$40M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Series B · modeled $550.5M · 2021-09-102021Series B · modeled $5.2M · 2025-02-28Series B · modeled $16.5M · 2025-06-202025
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
54%
Survival probability
36% low · 66% high
1.54×/yr
Annual markup
1.86×/yr upside case
1.0 yr
Elapsed time used
1.0 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
23 mo
Avg between rounds
$7.3M/yr
Capital velocity
4.8 yr
On record since
2021
First round
3
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 3.8× above median
This company$27.6M
Sector median$7.2M
Latest round — vs other Series B rounds in sector (real $, this stage) 0.2× of median
This company$3.5M
Sector median$17.5M
Modeled value — vs sector median (estimate, all stages) 0.3× of median
This company$16.5M
Sector median$64.2M

Raised more than 73% of sector peers (real $). Modeled value above 26% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series B) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #81 of 94.

This companyCohort peer
$10.0M$100.0M$1.0B$10.0M$100.0M$1.0BCapital raised (log)MarvelBiome, Inc. · Series B Raised $54.9M · modeled $163.2M (est)Iantrek, Inc. · Series B Raised $58.2M · modeled $152.4M (est)Dualitas Therapeutics, Inc. · Series B Raised $32.6M · modeled $150.4M (est)Antares Therapeutics, Inc. · Series B Raised $70.0M · modeled $149.7M (est)OrthoBio Therapeutics, Inc. · Series B Raised $31.4M · modeled $147.5M (est)Medcura, Inc. · Series B Raised $40.9M · modeled $145.0M (est)Neurolutions Inc · Series B Raised $26.5M · modeled $144.9M (est)Renasant Bio, Inc. · Series B Raised $55.5M · modeled $144.0M (est)Caldera Therapeutics, Inc. · Series B Raised $37.5M · modeled $139.2M (est)VitriVax, Inc. · Series B Raised $29.4M · modeled $136.9M (est)DiaMedica Therapeutics Inc. · Series B Raised $110.4M · modeled $136.3M (est)OmniAb, Inc. · Series B Raised $30.0M · modeled $130.5M (est)Neutrolis Inc. (this company) Raised $27.6M · modeled $16.5M (est)Neutrolis Inc.
CompanyStageRaised · realValue · estvs peer med.
MarvelBiome, Inc.Series B$54.9M$163.2M2.11×
Iantrek, Inc.Series B$58.2M$152.4M1.97×
Dualitas Therapeutics, Inc.Series B$32.6M$150.4M1.94×
Antares Therapeutics, Inc.Series B$70.0M$149.7M1.93×
OrthoBio Therapeutics, Inc.Series B$31.4M$147.5M1.90×
Medcura, Inc.Series B$40.9M$145.0M1.87×
Neurolutions IncSeries B$26.5M$144.9M1.87×
Renasant Bio, Inc.Series B$55.5M$144.0M1.86×
Caldera Therapeutics, Inc.Series B$37.5M$139.2M1.80×
VitriVax, Inc.Series B$29.4M$136.9M1.77×
DiaMedica Therapeutics Inc.Series B$110.4M$136.3M1.76×
OmniAb, Inc.Series B$30.0M$130.5M1.68×
Neutrolis Inc. this companySeries B$27.6M$16.5M0.21×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series B$23.1M2021-09-10$128.5M$550.5M90%
Series B$965K2025-02-28$5.4M$5.2M90%
Series B$3.5M2025-06-20$19.4M$16.5M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series B$23.1M2021-09-10
    • First recorded raise — entered as Series B.
    • 28 investors on this round.
  2. Series B$965K2025-02-28
    • Raised again after 42 mo — slower than the ~14 mo sector norm.
    • Round 24.0× smaller than the prior — bridge or down round.
    • 9 investors on this round.
  3. Series B$3.5M2025-06-20
    • Came back fast: 4 mo vs the ~14 mo sector norm.
    • Round 3.6× larger than the prior — scaling up.
    • 1 investor on this round.
Intelligence
2027 ~Q2
Modeled next raise · ~23mo cadence
$10.5M
Modeled next size est.range $6.8M$16.8M
3.6×
Last step-up
$7.3M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Abdul Hakkim Rahamathullah1 other2021-09
Anthony Hakkim Aiudi2021-09
Gerald Hakkim Chan2021-09
John Hakkim Sundy2025-02
Toby Hakkim Fox2021-09
Registry & provenance

Neutrolis Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1788926
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Morphogenesis IncBiotechnologySeries B$27.9M$15.1Msame sector · same stage
Euthymics Bioscience, Inc.BiotechnologySeries B$31.3M$11.9Msame sector · same stage
Xenter, Inc.BiotechnologySeries B$23.5M$15.5Msame sector · same stage
PrimeGen Biotech LLCBiotechnologySeries B$22.5M$15.9Msame sector · same stage
Aerovance IncBiotechnologySeries B$22.5M$19.8Msame sector · same stage
SeQure Dx Inc.BiotechnologySeries B$22.3M$20.2Msame sector · same stage
Revelar Biotherapeutics, Inc.BiotechnologySeries B$18.5M$20.0Msame sector · same stage
BlinkBio, Inc.BiotechnologySeries B$43.6M$20.8Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Neurelis, Inc.BiotechnologySeries D+$3.8B87%
Nexsis Biosciences LLCBiotechnologyPre-Seed$16.1M86%
Nativis, Inc.BiotechnologySeries A$16.3M85%
NERx Biosciences, Inc.BiotechnologyPre-Seed$4.8M85%
LeukoDx, Inc.BiotechnologySeries A$180.8M85%
Stabilux Biosciences, Inc.BiotechnologyPre-Seed$2.9M85%
Nexgenia Inc.BiotechnologySeed$5.3M85%
Leuko Labs, Inc.BiotechnologySeed$55.3M85%
Frequently asked
How much funding has Neutrolis Inc. raised?
Neutrolis Inc. has raised approximately $27.6M in disclosed capital across 3 recorded financing rounds, aggregated from public filings.
What is Neutrolis Inc.'s estimated valuation?
Provath's modeled valuation for Neutrolis Inc. is approximately $16.5M (modeled range $7.0M–$24.5M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Neutrolis Inc. at?
Neutrolis Inc.'s latest modeled financing stage is Series B. Its most recent recorded round closed around Fri Jun 20.
What does Neutrolis Inc. do and where is it based?
Neutrolis Inc. operates in the Biotechnology sector, based in CAMBRIDGE.
Explore related

See where Neutrolis Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Neutrolis Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.